Revlimid Hits Target in Newly Diagnosed Myeloma Patients
By Catherine Shaffer
Staff Writer
Staff Writer
Thursday, July 11, 2013
Celgene International Sarl's successful multiple myeloma drug, Revlimid (lenolidomide), met an important benchmark in newly diagnosed patients in a Phase III study.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.